CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
暂无分享,去创建一个
R. Varadhan | L. Gondek | T. Karantanos | Richard J. Jones | M. Levis | S. Yegnasubramanian | Patric Teodorescu | T. Jain | M. Arvanitis | A. DeZern | T. Rajkhowa | W. B. Dalton | C. Bonifant | G. Ghiaur | B. Perkins | B. Paun | I. Christodoulou | Christopher A Esteb | Marios Arvanitis | W. Dalton
[1] M. Andreeff,et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. , 2022, The Lancet. Haematology.
[2] R. Varadhan,et al. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy , 2022, Leukemia & lymphoma.
[3] R. Varadhan,et al. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia , 2021, bioRxiv.
[4] T. Karantanos,et al. Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome. , 2021, Best practice & research. Clinical haematology.
[5] R. Varadhan,et al. Gender‐related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes , 2021, British journal of haematology.
[6] D. Faller,et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML , 2021, Leukemia.
[7] S. Sozzani,et al. Molecular Basis for CCRL2 Regulation of Leukocyte Migration , 2020, Frontiers in Cell and Developmental Biology.
[8] E. Leifer,et al. A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102 , 2020, Transplantation and Cellular Therapy.
[9] S. Karanika,et al. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. , 2020, Blood advances.
[10] Liping Liu,et al. Mycobacterium tuberculosis Heat-Shock Protein 16.3 Induces Macrophage M2 Polarization Through CCRL2/CX3CR1 , 2019, Inflammation.
[11] Xiaomei Ma,et al. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. , 2019, Blood reviews.
[12] O. Fuchs. Recent Developments in Myelodysplastic Syndromes , 2019 .
[13] Duonan Yu,et al. Gender disparity in the survival of patients with primary myelodysplastic syndrome , 2019, Journal of Cancer.
[14] P. Skipp,et al. Proteomic Analysis of Azacitidine-Induced Degradation Profiles Identifies Multiple Chromatin and Epigenetic Regulators Including Uhrf1 and Dnmt1 as Sensitive to Azacitidine. , 2019, Journal of proteome research.
[15] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[16] T. Shi,et al. Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome , 2018, Proceedings of the National Academy of Sciences.
[17] Frederik Otzen Bagger,et al. BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles , 2018, Nucleic Acids Res..
[18] Y. Tohyama,et al. An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS , 2018, Leukemia.
[19] Xiaomei Ma,et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. , 2018, Blood.
[20] A. Mantovani,et al. The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage. , 2017, Blood.
[21] Susan R. Wilson,et al. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. , 2017, Cell reports.
[22] D. Maucort-Boulch,et al. An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia , 2016, Clinical Cancer Research.
[23] R. Dummer,et al. Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration , 2016, Oncotarget.
[24] B. Broom,et al. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer , 2016, Oncotarget.
[25] Sheng Wei,et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. , 2015, Blood.
[26] H. Kantarjian,et al. Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium , 2015, Cancer.
[27] G. Garcia-Manero,et al. An MDS xenograft model utilizing a patient-derived cell line , 2014, Leukemia.
[28] M. Voso,et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine , 2013, Leukemia.
[29] H. Hsu,et al. MDM2 Overexpression Deregulates the Transcriptional Control of RB/E2F Leading to DNA Methyltransferase 3A Overexpression in Lung Cancer , 2012, Clinical Cancer Research.
[30] Jie Shen,et al. Expression of DNMT1 and DNMT3a Are Regulated by GLI1 in Human Pancreatic Cancer , 2011, PloS one.
[31] B. Esterni,et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] N. Van Rooijen,et al. 5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia , 2010, mAbs.
[33] R. Ganetzky,et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] C. Hsiao,et al. Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. , 2008, Nucleic acids research.
[35] John D. Storey,et al. Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable Analysis , 2007, PLoS genetics.
[36] M. Newton,et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. , 2007, Cancer research.
[37] H. Heslop,et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.
[38] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[39] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] M. Day,et al. Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway. , 2005, Cancer research.
[41] J. Christman,et al. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.
[42] N. C. Price,et al. Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. , 1999, Journal of molecular biology.
[43] J. Mesirov,et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.
[44] C. Plass,et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells , 2009, Leukemia.